Home›Search›Cancer Biotherapy and Radiopharmaceuticals

Cancer Biotherapy and Radiopharmaceuticals

Mary Ann Liebert Inc. · United States

ISSN1084-9785eISSN1557-8852

SJR Q2✓ WOS SCIE✓ Scopus / SJR

Impact Factor & Quartile · Web of Science (JCR)

✓ Indexed in the Web of Science Core Collection (SCIE) — Clarivate publishes an official Journal Impact Factor and JCR quartile for this journal.

See the official Impact Factor & quartile on the journal’s page ↗

The Impact Factor & JCR quartile are licensed by Clarivate — we link you to the official source instead of reprinting a number that can go out of date. Open metrics below: SCImago Q2. Source: Clarivate Journal Citation Reports.

📊 Standing in its field

Where this journal ranks among others in the same subject area.

SJR · Scopus

Top 50% in field

Clarivate’s JCR quartile is a separate ranking and may differ

SJR Scorei

0.498

H-Indexi

SNIPi

0.57

Total Worksi

2,489

Total Citationsi

43,381

2yr Mean Citednessi

0.84

Open Impact Factor alternative

Aims & Scope

Subject areas: Medicine, Research & Experimental; Oncology; Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging; Radiology, Nuclear Medicine and Imaging; Medicine (miscellaneous); Pharmacology; Cancer Research.

General Information

Country / RegionUnited States

Primary LanguageEnglish

1st Year Published—

FrequencyBimonthly

StatusActive

Total Publications2,489

Publisher OrgMary Ann Liebert, Inc.

Visit Journal Website

Submission Info

Publishing ModelSubscription

Peer Review—

OA License—

OA Rate—

Ethics & Quality

COPE Member✗ No

OASPA Member✗ No

Not on Predatory Lists✓ Yes

Think.Check.Submit Compliance

thinkchecksubmit.org

6/11 · 55%

✅

Do you know the journal / publisher?

Mary Ann Liebert Inc.

✅

Does the journal have a website?

✓ Linked

✅

Is the ISSN verified?

1084-9785 / 1557-8852

✅

Indexed in a trusted database?

WoS, Scopus, PubMed

❌

Peer review process documented?

N/A

❌

Follows ethical publishing standards (COPE)?

N/A

✅

Not on predatory/blacklists?

✓ Clean

❌

Long-term digital preservation?

N/A

❌

Plagiarism detection in place?

N/A

❌

Listed in DOAJ (verified OA)?

N/A

✅

Primary language documented?

English

A twelfth criterion — whether APC fees are clearly disclosed — is not scored here; it is left out of the total rather than counted as a failure. Publication charges appear in the metrics card above.

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Publication & Citation Trend

Articles published

Citations received

1.6k

2019

219

3.9k

2020

121

923

2021

334

2022

133

2023

138

2024

2025

2026

Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

Radiology, Nuclear Medicine and ImagingQ2

Medicine (miscellaneous)Q3

OncologyQ3

PharmacologyQ3

Cancer ResearchQ4

Subject Classification

Web of Science Categories

Medicine, Research & ExperimentalOncologyPharmacology & PharmacyRadiology, Nuclear Medicine & Medical Imaging

Scopus Categories

PharmacologyRadiology, Nuclear Medicine and ImagingCancer ResearchOncologyMedicine (miscellaneous)

Research Topics (OpenAlex)

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and ApplicationsMonoclonal and Polyclonal Antibodies ResearchCancer-related molecular mechanisms researchImmunotherapy and Immune Responses

Frequently asked questions about Cancer Biotherapy and Radiopharmaceuticals

Is Cancer Biotherapy and Radiopharmaceuticals a predatory journal?

PubScope has no integrity flags on record for Cancer Biotherapy and Radiopharmaceuticals: it is indexed in Web of Science, Scopus, and is not on DOAJ's withdrawn list. Indexing is a transparency signal, not a guarantee — always confirm fit and policies before submitting.

What is the impact factor of Cancer Biotherapy and Radiopharmaceuticals?

Cancer Biotherapy and Radiopharmaceuticals is indexed in the Web of Science Core Collection, so Clarivate publishes an official Journal Impact Factor for it (since the 2023 Journal Citation Reports, every Core Collection journal — including Arts & Humanities and Emerging Sources titles — receives one). PubScope links to Clarivate's official source rather than reprinting the number, which can be out of date. Its open 2-year mean citedness is 0.84.

Is Cancer Biotherapy and Radiopharmaceuticals indexed in Scopus and Web of Science?

Cancer Biotherapy and Radiopharmaceuticals is indexed in Web of Science, Scopus.